Ken Griffin Allakos Inc. Transaction History

Citadel Advisors LLC

$559 Billion
Q4 2024

A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Allakos Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 3,900 shares of ALLK stock, worth $1,014. This represents 0.0% of its overall portfolio holdings.

Number of Shares

3,900

Previous 30,300 87.13%

Holding current value

$1,014

Previous $19,000 78.95%

% of portfolio

0.0%

Previous 0.0%

24 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 14, 2025	SELL	$0.62 - $1.5 $82,864 - $200,479	-133,653 Reduced 7.47%	1,656,420 $2 Million
Q3 2024 Nov 14, 2024	SELL	$0.54 - $0.92 $386,817 - $659,022	-716,329 Reduced 28.58%	1,790,073 $1.16 Million
Q2 2024 Aug 14, 2024	SELL	$1.0 - $1.45 $540,181 - $783,262	-540,181 Reduced 17.73%	2,506,402 $2.51 Million
Q1 2024 May 15, 2024	SELL	$1.02 - $3.23 $202,305 - $640,634	-198,339 Reduced 6.11%	3,046,583 $3.84 Million
Q4 2023 Feb 14, 2024	SELL	$1.72 - $3.18 $1.55 Million - $2.87 Million	-902,113 Reduced 21.75%	3,244,922 $8.86 Million
Q3 2023 Nov 14, 2023	BUY	$2.13 - $5.55 $2.59 Million - $6.75 Million	1,215,939 Added 41.48%	4,147,035 $9.41 Million
Q2 2023 Aug 14, 2023	BUY	$3.6 - $5.25 $695,016 - $1.01 Million	193,060 Added 7.05%	2,931,096 $12.8 Million
Q1 2023 May 15, 2023	BUY	$4.3 - $8.27 $2.81 Million - $5.4 Million	653,211 Added 31.33%	2,738,036 $12.2 Million
Q4 2022 Feb 14, 2023	BUY	$5.66 - $8.42 $2.24 Million - $3.33 Million	394,985 Added 23.37%	2,084,825 $17.6 Million
Q3 2022 Nov 14, 2022	BUY	$3.02 - $6.12 $284,142 - $575,812	94,087 Added 5.9%	1,689,840 $10.3 Million
Q2 2022 Aug 15, 2022	BUY	$2.6 - $6.14 $577,153 - $1.36 Million	221,982 Added 16.16%	1,595,753 $5 Million
Q1 2022 May 16, 2022	BUY	$5.08 - $9.81 $5.29 Million - $10.2 Million	1,041,997 Added 314.07%	1,373,771 $7.83 Million
Q4 2021 Feb 14, 2022	BUY	$8.55 - $111.89 $2.65 Million - $34.7 Million	309,683 Added 1401.85%	331,774 $3.25 Million
Q3 2021 Nov 15, 2021	SELL	$76.53 - $110.43 $773,182 - $1.12 Million	-10,103 Reduced 31.38%	22,091 $2.34 Million
Q2 2021 Aug 16, 2021	SELL	$85.37 - $114.1 $3.41 Million - $4.56 Million	-39,992 Reduced 55.4%	32,194 $2.75 Million
Q1 2021 May 17, 2021	BUY	$109.73 - $153.66 $5.04 Million - $7.06 Million	45,967 Added 175.32%	72,186 $8.29 Million
Q4 2020 Feb 16, 2021	SELL	$79.58 - $152.45 $3.83 Million - $7.34 Million	-48,152 Reduced 64.75%	26,219 $3.67 Million
Q3 2020 Nov 16, 2020	SELL	$66.43 - $90.99 $2.79 Million - $3.82 Million	-41,976 Reduced 36.08%	74,371 $6.06 Million
Q2 2020 Aug 14, 2020	SELL	$44.04 - $80.69 $243,012 - $445,247	-5,518 Reduced 4.53%	116,347 $8.36 Million
Q1 2020 May 15, 2020	BUY	$44.49 - $93.39 $4.66 Million - $9.77 Million	104,647 Added 607.78%	121,865 $5.42 Million
Q4 2019 Feb 14, 2020	BUY	$66.49 - $137.73 $1.14 Million - $2.37 Million	17,218 New	17,218 $1.64 Million
Q2 2019 Aug 14, 2019	SELL	$36.0 - $44.73 $805,464 - $1 Million	-22,374 Closed	0 $0
Q1 2019 May 15, 2019	BUY	$33.79 - $51.99 $620,114 - $954,120	18,352 Added 456.29%	22,374 $0
Q4 2018 Feb 14, 2019	BUY	$31.59 - $62.65 $127,054 - $251,978	4,022 New	4,022 $210,000

Others Institutions Holding ALLK

# of Institutions

Shares Held

68.8M

Call Options Held

20.9K

Put Options Held

View Full List

About Allakos Inc.

Ticker ALLK
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 84,726,096
Market Cap $22M
Description
Allakos Inc., a clinical stage biopharmaceutical company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases. The company's lead monoclonal antibody is lirentelimab (AK002), which is in a Phase III study for the treatment of eosinophilic gastritis and...

More about ALLK

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Account